Boditech Med Executive and Leadership Team

Yule Choi, the Chief Executive Officer at Boditech Med, directs the overarching corporate strategy and global market expansion initiatives. Overseeing the commercial trajectory, the Chief Executive Officer ensures that diagnostic solutions reach healthcare providers across diverse international markets. This leadership role involves managing investor relations and aligning internal resources with the long-term vision of providing accessible point-of-care testing. By optimizing operational efficiency, Yule Choi directly impacts the company's ability to scale production of the 85 proprietary biomarkers. The Chief Executive Officer maintains rigorous standards for quality control, ensuring that every diagnostic tool meets the evolving needs of clinicians. Through strategic partnerships and market analysis, the Chief Executive Officer secures the competitive position of the firm within the global in-vitro diagnostics sector. Ultimately, Choi drives sustainable growth and reinforces the commitment to improving health outcomes on a worldwide scale.

Eui-Yul Choi, the Co-Founder & Chief Executive Officer at Boditech Med, architects the foundational mission and long-term research roadmap for the organization. Overseeing the integration of scientific discovery with commercial application, the Co-Founder & Chief Executive Officer ensures that diagnostic innovation remains at the forefront of the business model. This leadership role involves guiding the development of new biomarkers to support capillary and venous blood testing. By fostering a culture of continuous improvement, Eui-Yul Choi directly impacts the efficacy of diagnostic solutions used by clinicians in 120 countries. The Co-Founder & Chief Executive Officer manages the alignment between laboratory research and market demands, ensuring that every product addresses critical healthcare gaps. Through visionary leadership, the Co-Founder & Chief Executive Officer sustains the company's reputation as a leader in point-of-care testing. Ultimately, Choi secures the future of the firm by prioritizing technological excellence and patient-centric diagnostic advancements.

Euiyul Choi, the Founder & Chief Executive Officer at Boditech Med, drives the strategic vision and organizational culture that defines the company's presence in the in-vitro diagnostics industry. Overseeing the expansion of the diagnostic portfolio, the Founder & Chief Executive Officer ensures that the firm maintains its status as a global leader in point-of-care testing. This leadership role involves navigating the complexities of the KOSDAQ-listed entity while maintaining focus on the core mission of improving health and quality of life. By championing the development of 85 biomarkers, Euiyul Choi directly impacts the diagnostic capabilities available to healthcare professionals worldwide. The Founder & Chief Executive Officer coordinates with the board to ensure financial stability and operational growth. Through consistent dedication to innovation, the Founder & Chief Executive Officer strengthens the market reach of the company. Ultimately, Choi ensures that the organization remains a vital partner for clinicians seeking reliable, rapid diagnostic solutions.

Keith Nahm, the Chief Technology Officer at Boditech Med, directs the technical infrastructure and engineering processes required to produce high-quality diagnostic solutions. Overseeing the research and development department, the Chief Technology Officer ensures that all 85 biomarkers meet stringent performance standards for capillary and venous blood testing. This leadership role involves managing the transition from laboratory prototypes to mass-produced diagnostic kits. By optimizing the technological framework, Keith Nahm directly impacts the precision and reliability of the company's in-vitro diagnostic tools. The Chief Technology Officer collaborates with cross-functional teams to integrate new testing methodologies into the existing product line. Through the implementation of advanced engineering practices, the Chief Technology Officer supports the company's goal of providing rapid, accurate results to clinicians in 120 countries. Ultimately, Nahm secures the technical integrity of the firm's offerings, ensuring that every diagnostic solution delivers consistent value to patients and healthcare providers.